667 related articles for article (PubMed ID: 33939108)
21. Transforming CLL management with immunotherapy: Investigating the potential of CAR T-cells and bispecific antibodies.
Borogovac A; Siddiqi T
Semin Hematol; 2024 Apr; 61(2):119-130. PubMed ID: 38290860
[TBL] [Abstract][Full Text] [Related]
22. Making CAR T Cells a Solid Option for Solid Tumors.
Schmidts A; Maus MV
Front Immunol; 2018; 9():2593. PubMed ID: 30467505
[TBL] [Abstract][Full Text] [Related]
23. Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy.
Karches CH; Benmebarek MR; Schmidbauer ML; Kurzay M; Klaus R; Geiger M; Rataj F; Cadilha BL; Lesch S; Heise C; Murr R; Vom Berg J; Jastroch M; Lamp D; Ding J; Duewell P; Niederfellner G; Sustmann C; Endres S; Klein C; Kobold S
Clin Cancer Res; 2019 Oct; 25(19):5890-5900. PubMed ID: 31285373
[TBL] [Abstract][Full Text] [Related]
24. Tumor Secretome to Adoptive Cellular Immunotherapy: Reduce Me Before I Make You My Partner.
Etxebeste-Mitxeltorena M; Del Rincón-Loza I; Martín-Antonio B
Front Immunol; 2021; 12():717850. PubMed ID: 34447383
[TBL] [Abstract][Full Text] [Related]
25. Charting new paradigms for CAR-T cell therapy beyond current Achilles heels.
Li Y; Hu Z; Li Y; Wu X
Front Immunol; 2024; 15():1409021. PubMed ID: 38751430
[TBL] [Abstract][Full Text] [Related]
26. T Cell-Redirecting Strategies to 'STAb' Tumors: Beyond CARs and Bispecific Antibodies.
Blanco B; Compte M; Lykkemark S; Sanz L; Alvarez-Vallina L
Trends Immunol; 2019 Mar; 40(3):243-257. PubMed ID: 30827461
[TBL] [Abstract][Full Text] [Related]
27. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
28. Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy.
Chuntova P; Downey KM; Hegde B; Almeida ND; Okada H
Front Immunol; 2018; 9():3062. PubMed ID: 30740109
[TBL] [Abstract][Full Text] [Related]
29. Immunobiology of chimeric antigen receptor T cells and novel designs.
Walsh Z; Yang Y; Kohler ME
Immunol Rev; 2019 Jul; 290(1):100-113. PubMed ID: 31355496
[TBL] [Abstract][Full Text] [Related]
30. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells.
Darowski D; Kobold S; Jost C; Klein C
MAbs; 2019; 11(4):621-631. PubMed ID: 30892136
[TBL] [Abstract][Full Text] [Related]
31. CAR T Cell Therapy for Neuroblastoma.
Richards RM; Sotillo E; Majzner RG
Front Immunol; 2018; 9():2380. PubMed ID: 30459759
[TBL] [Abstract][Full Text] [Related]
32. Use of a Single CAR T Cell and Several Bispecific Adapters Facilitates Eradication of Multiple Antigenically Different Solid Tumors.
Lee YG; Marks I; Srinivasarao M; Kanduluru AK; Mahalingam SM; Liu X; Chu H; Low PS
Cancer Res; 2019 Jan; 79(2):387-396. PubMed ID: 30482775
[TBL] [Abstract][Full Text] [Related]
33. Engineering Immune Cells for
Blanco B; Ramírez-Fernández Á; Alvarez-Vallina L
Front Immunol; 2020; 11():1792. PubMed ID: 32903593
[TBL] [Abstract][Full Text] [Related]
34. Adoptive T cell therapy: points to consider.
Yee C
Curr Opin Immunol; 2018 Apr; 51():197-203. PubMed ID: 29730057
[TBL] [Abstract][Full Text] [Related]
35. From antibodies to living drugs: Quo vadis cancer immunotherapy?
Szöőr Á; Szöllősi J; Vereb G
Biol Futur; 2021 Mar; 72(1):85-99. PubMed ID: 34554498
[TBL] [Abstract][Full Text] [Related]
36. [Bispecific antibodies: An old story with a bright future… with CAR-T cells!].
Riffard C; Teillaud JL
Bull Cancer; 2021 Oct; 108(10S):S168-S180. PubMed ID: 34920800
[TBL] [Abstract][Full Text] [Related]
37. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
38. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
39. Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.
Badar T; Shah NN
Curr Treat Options Oncol; 2020 Feb; 21(2):16. PubMed ID: 32025828
[TBL] [Abstract][Full Text] [Related]
40. CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Wagner J; Wickman E; DeRenzo C; Gottschalk S
Mol Ther; 2020 Nov; 28(11):2320-2339. PubMed ID: 32979309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
